JP2023547475A - Ｂｅｔブロモドメイン阻害剤及びナトリウム依存性グルコース輸送体２阻害剤の組み合わせを用いて腎機能を改善するための方法 - Google Patents

Ｂｅｔブロモドメイン阻害剤及びナトリウム依存性グルコース輸送体２阻害剤の組み合わせを用いて腎機能を改善するための方法 Download PDF

Info

Publication number
JP2023547475A
JP2023547475A JP2023526313A JP2023526313A JP2023547475A JP 2023547475 A JP2023547475 A JP 2023547475A JP 2023526313 A JP2023526313 A JP 2023526313A JP 2023526313 A JP2023526313 A JP 2023526313A JP 2023547475 A JP2023547475 A JP 2023547475A
Authority
JP
Japan
Prior art keywords
egfr
alkyl
alkoxy
diabetes
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547475A5 (https=
Inventor
ユージーン レビオダ，ケネス
ロス アームストロング ハリデイ，クリストファー
ナイーム カーン，アジズ
Original Assignee
レスバーロジックス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レスバーロジックス コーポレイション filed Critical レスバーロジックス コーポレイション
Publication of JP2023547475A publication Critical patent/JP2023547475A/ja
Publication of JP2023547475A5 publication Critical patent/JP2023547475A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023526313A 2020-10-30 2021-10-29 Ｂｅｔブロモドメイン阻害剤及びナトリウム依存性グルコース輸送体２阻害剤の組み合わせを用いて腎機能を改善するための方法 Pending JP2023547475A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063107853P 2020-10-30 2020-10-30
US63/107,853 2020-10-30
PCT/IB2021/060043 WO2022091028A1 (en) 2020-10-30 2021-10-29 Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Publications (2)

Publication Number Publication Date
JP2023547475A true JP2023547475A (ja) 2023-11-10
JP2023547475A5 JP2023547475A5 (https=) 2024-10-24

Family

ID=81382005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526313A Pending JP2023547475A (ja) 2020-10-30 2021-10-29 Ｂｅｔブロモドメイン阻害剤及びナトリウム依存性グルコース輸送体２阻害剤の組み合わせを用いて腎機能を改善するための方法

Country Status (11)

Country Link
US (1) US20230381178A1 (https=)
EP (1) EP4236955A4 (https=)
JP (1) JP2023547475A (https=)
KR (1) KR20230098275A (https=)
CN (1) CN116390721A (https=)
AU (1) AU2021368618B2 (https=)
CA (1) CA3197706A1 (https=)
IL (1) IL301831A (https=)
MX (1) MX2023004671A (https=)
TW (1) TW202233194A (https=)
WO (1) WO2022091028A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114650824A (zh) 2019-11-05 2022-06-21 雷斯韦洛吉克斯公司 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507899A (ja) * 2015-03-13 2018-03-22 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4678242A3 (en) * 2013-04-18 2026-03-18 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
AU2015210898A1 (en) * 2014-01-31 2016-07-28 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507899A (ja) * 2015-03-13 2018-03-22 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JULIO M. MARTINEZ-MORENO ET AL., MOLECULAR SCIENCES, vol. 21, JPN6025048731, 9 June 2020 (2020-06-09), pages 1 - 26, ISSN: 0005743842 *
K.K. RAY, EUROPEAN HEART JOURNAL, vol. Vol.40, Issue Supplement_1, JPN6025048734, 2019, pages 4608, ISSN: 0005743839 *
MARTA RUIZ-ORTEGA ET AL., NATURE REVIEWS NEPHROLOGY, vol. 16, JPN6025048732, May 2020 (2020-05-01), pages 269 - 288, ISSN: 0005743841 *
古川聡子 ほか, 医学検査, vol. 67, no. 4, JPN6025048733, 2018, pages 563 - 567, ISSN: 0005743840 *

Also Published As

Publication number Publication date
KR20230098275A (ko) 2023-07-03
WO2022091028A1 (en) 2022-05-05
CA3197706A1 (en) 2022-05-05
EP4236955A4 (en) 2024-08-07
TW202233194A (zh) 2022-09-01
AU2021368618A1 (en) 2023-05-04
AU2021368618A9 (en) 2024-09-05
AU2021368618B2 (en) 2025-02-27
IL301831A (en) 2023-06-01
US20230381178A1 (en) 2023-11-30
MX2023004671A (es) 2023-05-19
EP4236955A1 (en) 2023-09-06
CN116390721A (zh) 2023-07-04

Similar Documents

Publication Publication Date Title
US20240374562A1 (en) Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
KR102935008B1 (ko) Bet 브로모도메인 억제제 및 나트륨 의존 글루코스 수송 2 억제제와 병용하여 주요 부정적 심혈관 사건 (mace)을 치료 및/또는 예방하는 방법
JP2023547475A (ja) Ｂｅｔブロモドメイン阻害剤及びナトリウム依存性グルコース輸送体２阻害剤の組み合わせを用いて腎機能を改善するための方法
US20230398137A1 (en) Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
JP7763761B2 (ja) Ｂｅｔブロモドメイン阻害剤およびジペプチジルペプチダーゼ４阻害剤の組合せによる主要有害心血管イベント（ｍａｃｅ）の治療方法および／または予防方法
EA049336B1 (ru) Способы улучшения функции почек при помощи комбинации ингибитора бромодомена bet и ингибитора натрий-зависимого транспортера глюкозы 2 типа
HK40081394B (en) Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
HK40081394A (en) Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
EA047426B1 (ru) Способы лечения и/или предотвращения серьезных нежелательных сердечно-сосудистых явлений (снсся) с помощью комбинации ингибитора бромодомена bet и ингибитора натрий-глюкозного котранспортера 2-го типа

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260225